Introduction
============

Studying epigenetic modifications to elucidate molecular mechanisms underlying disease has been in the forefront of research over the last decade, especially with respect to neurodevelopmental and neuropsychiatric disorders. The most common epigenetic modification is 5-methylcytosine (5mC), which is involved in transcriptional silencing, X-chromosome inactivation, and genomic imprinting, to name a few \[[@bpw002-B1]\]. Although regarded as a genomically stable mark, recent advances have shed light on 5mC's oxidative products, namely 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which arise through successive oxidation reactions catalyzed by the ten-eleven translocation (TET) enzymes \[[@bpw002-B2]\]. Given the growing interest in the study of these modifications in the mammalian genome, a pressing issue is the development of low-cost, high-throughput technologies to analyze them \[[@bpw002-B6]\].

For many years, the 'gold standard' to methylation analyses has revolved around traditional sodium bisulfite conversion. Using this approach, cytosine, 5fC, and 5caC are converted to uracil following sodium bisulfite conversion and appear as thymine after sequencing, whereas 5mC and 5hmC are protected from this conversion and are read as cytosines after sequencing \[[@bpw002-B7], [@bpw002-B8]\]. The addition of a chemical (oxBS-Seq) \[[@bpw002-B8]\] or enzymatic (TAB-Seq) \[[@bpw002-B9]\] oxidation reaction, where 5hmC is converted to 5fC or 5mC is converted to 5caC, respectively, prior to sodium bisulfite conversion, has allowed for the discrimination of 5mC from 5hmC. However, since sequencing technologies to study genome-wide 5hmC at base pair resolution remain expensive when used genome wide with sufficient resolution, alternative methods are required to increase accessibility. Both TAB- and oxBS-Seq can be combined with reduced-representation bisulfite sequencing (RRBS) to interrogate CG-rich regions, such as CpG islands and promoters \[[@bpw002-B10], [@bpw002-B11]\]. Although this can dramatically decrease sequencing costs, low levels of 5hmC in these regions \[[@bpw002-B8]\] make it unlikely to yield relevant results. Similarly, combining TAB or oxBS with the Illumina Infinium 450K Methylation array (450K array) \[[@bpw002-B12]\] is not ideal because the probes on this array were specifically designed to investigate differential 5mC in tissues with low levels of 5hmC. This latter point is apparent in previous reports using oxBS combined with the 450K array, where a maximum of 80 000 loci on this array were found to contain 5hmC in two human brain regions \[[@bpw002-B13], [@bpw002-B15]\].

Most recently, an update to the 450K array was presented. The Infinium MethylationEPIC array (EPIC array) contains probes covering more than 850 000 CpGs in the human genome, including more than 90% of the probes on the 450K array. Of particular interest, the additional probes on the EPIC array have been designed to cover ENCODE enhancer and open chromatin regions, FANTOM5 enhancers, DNase hypersensitivity sites, non-CpG methylation sites identified in stem cells, and miRNA promoters, each of which has the potential to yield functionally relevant data in a variety of phenotypes.

In this report, using technical replicates of DNA from human brain, blood, and saliva, we combine oxBS with Illumina's EPIC array (oxBS-EPIC) to evaluate whether the EPIC array is suitable for studying 5hmC in these tissues. With information on more than 400 000 relevant loci, we show this technology to be suitable for large-scale 5mC and 5hmC analyses.

Materials and methods
=====================

Subjects
--------

Brain tissue from the cerebellum of an adult male, psychiatrically healthy control was obtained from the Douglas--Bell Canada Brain Bank (DBCBB), whereas human saliva and blood samples were obtained from two separate adult male, psychiatrically healthy individuals, respectively. Tissue from the DBCBB was dissected at 4**°**C, snap-frozen in liquid nitrogen, and stored at −80**°**C following standard procedures. The Quebec Coroner's office assessed the cause of death, and subsequently, the DBCBB obtained information on the subject's mental health through psychological autopsies using the Structured Clinical Interviews for DSM-IV Axis 1 \[[@bpw002-B16]\]. In addition, the brain tissue sample was assessed for absence of pathological processes by a neuropathologist. Written informed consent was obtained from next-of-kin (postmortem sample) or the individual himself (blood and saliva samples), and the Douglas Institute Research Ethics Board approved this study.

DNA extraction
--------------

Genomic DNA was extracted from brain tissue and blood using QIAGEN's QIAmp DNA Mini Kit (QIAGEN, cat \#: 51304) and FlexiGene DNA kit (QIAGEN, cat. \#: 51206), respectively. Saliva was collected in DNA Genotek's Oragene OG-250 containers (DNA Genotek, cat. \#: OG-250) and genomic DNA was extracted using DNA Genotek's prepIT-L2P reagents (DNA Genotek, cat. \#: PT-L2P). NanoDrop 2000 spectrophotometer and Quant-IT PicoGreen (Thermo Scientific, cat. \#: P7589) were used to assess the DNA quality and concentration.

Oxidative bisulfite conversion
------------------------------

The oxidative bisulfite conversion reaction was done using the CEGX True Methyl kit (Cambridge Epigenetix, Cat. \#: CEGXTMS). Briefly, 1 μg of DNA from all samples was purified and denatured. DNA from each subject was then split in two equal reactions, one of which underwent chemical oxidation followed by bisulfite conversion, the other underwent mock oxidation (oxidant replaced by water) followed by bisulfite conversion. All bisulfite reactions were cleaned up using a bead-based purification and final elution was in 12 μl of elution buffer.

Infinium MethylationEPIC array
------------------------------

Immediately following elution, all reactions were processed through the EPIC array protocol. Briefly, 7 μl of converted DNA was denatured with 1 μl of 0.4N sodium hydroxide prior to whole genome amplification on the MSA4 plate. All other steps were followed as per manufacturer's guidelines. Array bead chips were scanned on Illumina HiScan.

Data processing
---------------

Illumina's Infinium assays utilize methylated and unmethylated probes that bind to specific loci to determine the (hydroxy)methylation values at a given CpG. Beta values represent the measured (hydroxy)methylation values, based on the intensities of these two probes. Beta values range from 0 to 1, and can be thought of as a methylation percentage. For example, a beta value of 0.2 can be thought of as 20% (hydroxy)methylation. Processing and statistical analysis of the EPIC array data was performed using the R statistical language version 3.3.0 and various packages of the Bioconductor project \[[@bpw002-B17]\]. Specifically, minfi version 1.18.2 \[[@bpw002-B18]\] was used to load, apply SWAN normalization \[[@bpw002-B19]\], annotate probes, and filter probes with high detection *P*-values (\>0.01) across multiple samples (30%), probes mapping to known SNPs, and non-CpG methylation probes.

The threshold for calling 5hmC or 5mC was set to 0.0799, which corresponds to the 95th percentile of all negative Δβ~BS-oxBS~ values observed across all samples and sites \[[@bpw002-B15]\]. Detection of 5hmC or 5mC with the same tissue was called if the threshold value was exceeded in both replicates.

Representative gene analysis
----------------------------

Gene models as defined in the Bioconductor package *TxDb.Hsapiens.UCSC.hg19.knownGene* version 3.2.2 were used to define TSS5000 (5 kb upstream), gene body, and TES (5 kb downstream) regions. Genes for which one region overlapped with any region of a different gene were excluded. The remaining 13 695 TSS5000, gene bodies, and TES5000 were each split in 100 bins of equal relative size. Site measurements (β~BS~, β~ox~, Δβ~BS-oxBS~) were averaged within each bin and then averaged across genes.

Results
=======

Quality control measures of the oxBS assay and EPIC array
---------------------------------------------------------

As global levels of 5hmC differ between tissue types \[[@bpw002-B20]\], here, in technical replicates from three human biological tissues, we sought to compare whether the additional probes on the EPIC array yield valuable data for each modification. To do so, DNA from human cerebellum, blood, and saliva was extracted and split in two. Each aliquot was processed through the oxBS protocol independently and was loaded into separate wells on the EPIC array bead chip. Interrogation of the oxBS digestion and sequencing controls ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}) and comparison of the bisulfite conversion efficiencies from the oxBS kit with that of the commonly used Zymo EZ DNA Methylation bisulfite conversion kit ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}) confirm the efficiency of both the oxidative and the bisulfite conversion reagents in the oxBS kit. Furthermore, quality control measures from the array, which show comparable total signal between samples, appropriate hierarchical clustering, and expected multidimensional scaling, can be found in [Supplementary Fig. S3](#sup1){ref-type="supplementary-material"}.

Using oxBS, 5mC values are represented by the beta values in the oxBS fraction (β~oxBS~), whereas 5hmC values (Δβ~BS-oxBS~) are determined by subtracting β~oxBS~ from the beta values in the BS fraction (β~BS~). Technical replicates in all three specimens showed significant linear correlations for both Δβ~BS-oxBS~ (cerebellum: *r* = 0.91; blood: *r* = 0.38; saliva: *r* = 0.15; *P* \< 0.05 for all) and β~oxBS~ (cerebellum: *r* = 0.98; blood: *r* = 0.99; saliva: *r* = 0.98; *P* \< 0.05 for all) ([Fig. 1](#bpw002-F1){ref-type="fig"}a--f). The variability in the Δβ~BS-oxBS~*r*-coefficients across the three tissue types appears to be a consequence of the lower levels of 5hmC in blood and saliva. As such, these results suggest this method to be highly replicable. Figure 1oxBS-EPIC shows strong replicability in cerebellum, blood, and saliva. Scatter plots confirm the replicability of 5hmC in **(a)** brain (*r* = 0.91), **(b)** blood (*r* = 0.38), and **(c)** saliva (*r* = 0.15) and 5mC in **(d)** brain (*r* = 0.98), **(e)** blood (*r* = 0.99), and **(f)** saliva (*r* = 0.98) across two technical replicates. *P*-values are \< 0.05 for all comparisons.

Differing levels of 5mC and 5hmC in human tissues
-------------------------------------------------

After filtering based on quality control parameters, we were left with 831 828 probes. Δβ~BS-oxBS~ and β~oxBS~ values were mostly positive in all three tissue types, as expected ([Fig. 2](#bpw002-F2){ref-type="fig"}a and b). There were, however, negative Δβ~BS-oxBS~ values, which likely represent technical variations resulting from the oxBS and EPIC array protocols. To account for these areas of potential error, and in line with previous work using oxBS on the 450K array \[[@bpw002-B15]\], we considered probes to contain a detectable level of 5hmC if the probe's Δβ~BS-oxBS~ \> 0.0799 in both replicates, which represents the 95th percentile of negative Δβ~BS-oxBS~ values (see "Materials and Methods" section for additional information). Common to both replicates, there were 432 418 and 660 880 probes containing detectable 5hmC and 5mC in human cerebellum, 18 999 and 697 291 probes containing detectable 5hmC and 5mC in blood, and 27 478 and 694 234 probes containing detectable 5hmC and 5mC in saliva ([Fig. 2](#bpw002-F2){ref-type="fig"}c and d). Of these detectable probes, we found 2528 5hmC-containing and 642 032 5mC-containing loci to be common across all three tissues types ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). Probes containing detectable 5hmC common across the three tissue types showed a similar distribution of Δβ~BS-oxBS~ compared to the genome-wide probe set. Similarly, these probes were found across all chromosomes and genomic features ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). Interestingly, gene ontology analyses showed these common probes with detectable 5hmC to be related primarily to immune system and immune response ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The low number of overlapping sites for 5hmC is explained by the low abundance of this modification in tissues other than the brain \[[@bpw002-B13], [@bpw002-B22], [@bpw002-B23]\], and in this case in blood and saliva. In addition, this is consistent with the expectation that 5hmC shows a very strong tissue-specific variation \[[@bpw002-B20],[@bpw002-B24]\]. The overlap of 5mC-containing probes across three tissue types suggests a higher stability of 5mC across tissues, although this may be a function of the loci specifically chosen for this array. Together, these results show the ability of the EPIC array to detect and differentiate 5mC and 5hmC, especially in human brain tissue, when combined with oxBS. Figure 2Both 5hmC and 5mC are present at detectable levels in all three tissue types. **(a)** 5hmC and **(b)** 5mC detectability was determined using a Δβ threshold of 0.0799 (dashed line). **(c)** An average of 57.8 ± 0.3%, 7.4 ± 1.6%, and 12.5 ± 1.2% of loci contained detectable 5hmC in cerebellum, blood, and saliva, respectively. **(d)** Of all loci, \>80% showed detectable 5mC in all three tissue types, with an average of 81.3 ± 1.1%, 85.1 ± 0.3%, and 85.5 ± 1.5% in cerebellum, blood, and saliva, respectively. Data from (c) and (d) include 'all probes' regardless of annotation or genomic location.

Characterizing 5mC and 5hmC across chromosomes and genomic features
-------------------------------------------------------------------

Within each tissue, we aimed to see whether the number of probes with detectable 5mC and 5hmC varied across chromosomes. To do so, we plotted the number of loci with detectable 5hmC or 5mC per given chromosome, corrected for the total number of probes mapping to that particular chromosome on the array. For blood and saliva, although the absolute number of probes is low, we did observe an even distribution of detectable 5hmC loci across chromosomes. Interestingly, in cerebellum, \>50% of probes on each autosomal chromosome contain detectable 5hmC levels, with chromosome 19 being the only exception. Also in this tissue, chromosome X shows a similar fraction of detectable 5hmC compared to the autosomes, whereas chromosome Y shows a reduction ([Fig. 3](#bpw002-F3){ref-type="fig"}a). Unlike 5hmC, and as expected given the purpose of the array, \>75% of probes contain detectable 5mC across autosomes and sex chromosomes, regardless of tissue, with chromosome 19 again being the sole exception with the fraction being just short of this percentage ([Fig. 3](#bpw002-F3){ref-type="fig"}b). The decrease in loci containing both 5mC and 5hmC on chromosome 19 could be a result of it being the chromosome with the greatest gene density ([Supplementary Fig. S5](#sup1){ref-type="supplementary-material"}) \[[@bpw002-B27]\]. Nevertheless, the consistency of 5hmC and 5mC across chromosomes reinforces the value of this approach in genome-wide cytosine modification analyses and provides insight into the stability of 5hmC in mammalian brain DNA. Figure 3The EPIC array contains an equal distribution of probes with detectable 5hmC and 5mC across chromosomes. **(a)** Although the fraction of probes containing 5hmC in blood and saliva is greatly reduced, all three tissue types show an equal distribution across autosomes. Of particular importance, in cerebellum, \>50% of all probes on autosomes show detectable 5hmC, with the exception of chromosome 19, at\>48%. Detectability is reduced on sex chromosomes, primarily chromosome Y. **(b)** Also with the exception of chromosome 19, 5mC is detectable at \>75% of probes on all chromosomes in all three tissue types, including chrX and chrY.

We next looked at patterns of loci with detectable 5hmC and 5mC probes across genomic features annotated on the array, which include regions downstream of the transcription start sites (TSS200 and TSS1500), the 5′ untranslated region (5′ UTR), the first exon, exon boundaries, gene bodies, 3′ UTR, and intergenic regions. Similar to the analyses across chromosomes, we again plotted the number of loci with detectable 5hmC or 5mC per genomic feature, corrected for the total number of probes on the array mapping to that particular genomic feature. We show an increase in the number of probes with detectable 5hmC in gene bodies, exon boundaries, and intergenic regions, whereas the regions within 200 bp of the TSS and the annotated first exon showed the lowest levels of 5hmC-detecting probes ([Fig. 4](#bpw002-F4){ref-type="fig"}a). Although the fraction of probes containing detectable 5hmC is not an indication of the absolute levels of this modification in the particular region, these findings are in line with previous reports highlighting the abundance of 5hmC in gene bodies and enhancer regions \[[@bpw002-B28], [@bpw002-B29]\]. Following the same pattern of abundance as 5hmC from one feature to the next, nearly 100% of probes contained within the annotated exon boundaries, gene body, 3′ UTR, and intergenic regions showed detectable 5mC, while this value was reduced to \<75% for upstream regions of the gene (TSS200, TSS1500, 5′ UTR, and first exon) ([Fig. 4](#bpw002-F4){ref-type="fig"}b). Certainly, the large number of probes containing 5mC is not surprising since these probes were chosen specifically for this methylation array. Nevertheless, this profile was consistent across all tissue types, which lends to the notion that 5mC shows stable patterns across tissue types. Figure 4The additional probes added to the EPIC array provide substantial 5hmC data in regions likely to be phenotypically relevant. **(a)** The fraction of probes containing detectable 5hmC in cerebellum is highest in the gene body compared to proximal promoter regions and the first exon. Detectable 5hmC probes in blood and saliva follow a similar pattern, but, as expected, are greatly reduced in number. **(b)** The fraction of probes containing detectable 5mC is similar in all three tissue types and also shows the highest levels in intragenic and intergenic regions, apart from regions proximal to the TSS. The additional probes on the EPIC array in the **(c)** Fantom5 enhancers, **(d)** open chromatin regions, and **(e)** DNase hypersensitivity sites show a strong abundance of probes containing both 5mC and 5hmC, suggesting that this array is more suitable for discovery of differentially modified regions in case--control analyses.

We further analyzed annotated regions with putative functional properties, such as Fantom5 enhancer regions, DNase hypersensitivity sites, and regions of open chromatin. The fraction of loci with detectable 5mC was always \>75%, regardless of tissue ([Fig. 4](#bpw002-F4){ref-type="fig"}c--e, left half of graphs), whereas, for human brain in particular, 50% of the probes within these regions contained detectable 5hmC ([Fig. 4](#bpw002-F4){ref-type="fig"}c--e, right half of graphs). As expected due to the lower global levels of 5hmC, around 10% of probes associated with Fantom5 enhancers, DNase hypersensitivity sites, and regions of open chromatin contained detectable 5hmC in blood and saliva. Although gene ontology analyses did not identify specific differences in functional enrichment of 5hmC between DNase hypersensitivity sites, regions of open chromatin, and Fantom5 enhancer regions ([Supplementary Tables S2--S4](#sup1){ref-type="supplementary-material"}, respectively), in their entirety, these results confirm the utility of the tested methodology to identify 5hmC in different tissues, especially human brain.

Variance of 5mC and 5hmC across a representative gene
-----------------------------------------------------

The abundance of 5hmC in human brain and the inability of standard methods commonly used to study 5mC to differentiate between 5mC and 5hmC raises the question of how much of the variance in cytosine modifications across a gene may be accounted for by 5mC alone. To do so, we created an archetype gene comprising a 5 kb region upstream of the TSS, a region between the TSS and the TES, and a 5 kb region downstream of the TES. This archetype included β~oxBS~ (5mC) and β~BS~ (5mC + 5hmC) values representative of \>13 695 genes on this array. Given the low levels of 5hmC in blood and saliva, nearly all of the signal from the array was accounted for by 5mC ([Fig. 5](#bpw002-F5){ref-type="fig"}a and c). However, our results showed that the 5mC signal in human cerebellum accounted for approximately two-third of the total signal from cytosine modifications ([Fig. 5](#bpw002-F5){ref-type="fig"}b), at least in the genomic regions covered by the EPIC array. This finding supports the idea that studies in mammalian brain using bisulfite conversion alone may not properly measure total 5mC content, and that part of the published results may be explained by differences in 5hmC levels. Figure 55mC accounts for only two-third of the variance in cytosine modifications in human cerebellum. For blood (**a**), cerebellum (**b**), and saliva (**c**), β~oxBS~ (blue lines, 5mC) and β~BS~ (red lines, 5mC + 5hmC) were plotted from 5 kb upstream of the TSS (5 kb+) to the TSS, across the intragenic region to the TES, and 5 kb downstream of the TES (5 kb−) for \>13 695 genes containing detectable 5mC. For blood and saliva, the vast majority of cytosine modification signal from bisulfite-converted DNA is that of 5mC, with the gene body region in saliva samples showing slightly more contribution from 5hmC. For cerebellum, however, 5mC contributes to only two-third of the cytosine modification signals, not only in the gene body but also across the entire representative genome.

Discussion
==========

Enrichment-based approaches, such as 5hmC immunoprecipitation (hMeDIP) or selective chemical labeling (hMe-SEAL), have been combined with next-generation sequencing to allow for an effective, low-cost whole-genome analysis of 5hmC. To achieve base pair resolution, methodologies utilize modified bisulfite conversion protocols, such as oxBS- and TAB-Seq. However, with the high cost associated with whole-genome studies, alternative approaches became necessary. In this manuscript, we combine oxBS with the EPIC array to study both 5mC and 5hmC. Our results demonstrate not only the replicability of this methodology in all three tissue types, but also its ability to effectively study 5hmC in \>400 000 loci in human brain.

The increasing number of publications showing 5hmC in different tissue types brings to light several important caveats to consider when looking at previously published bisulfite-based results. Data generated using a bisulfite alone, whether combined with whole- or reduced-genome sequencing arrays, prevent researchers from dissociating 5mC from 5hmC. Certainly, this issue will be more prominent in studies using DNA from mammalian brain, regardless of platform, but it should not be overlooked in studies using tissues with lower levels of 5hmC or in studies using previous array technologies. As we move forward, researchers who generate data using bisulfite conversion alone should consider using the term cytosine *modifications* rather than *methylation*. Alternatively, the success of the oxBS-EPIC methodology presented in this manuscript provides researchers with an effective approach to simultaneously investigate both modifications, thereby adding validity to their findings.

The oxBS-EPIC methodology presented here may also provide insight into the debate on the function of cytosine modifications. On the one hand, it is proposed that 5mC's oxidative products are destined for demethylation. Specifically, 5fC and 5caC are targeted and excised by thymine DNA glycosylase and the base excision repair pathway \[[@bpw002-B30], [@bpw002-B31]\]. However, given the relative abundance of 5hmC in DNA from mammalian brain tissue we show here and shown elsewhere \[[@bpw002-B2], [@bpw002-B32]\], it is thought that this modification may also be stable \[[@bpw002-B33]\] and act as a transcriptional regulator \[[@bpw002-B28], [@bpw002-B29], [@bpw002-B32], [@bpw002-B34]\]. Of particular interest, compared to the 450K array, the EPIC array includes an additional 400 000 probes, most of which are located in regions such as Fantom5 enhancers, ENCODE enhancers and open chromatin regions, and DNase 1 hypersensitivity sites. The majority of the probes with detectable 5hmC discovered in this manuscript are located within these added probes, each of which has proposed transcriptional regulatory properties. Taken together, although the oxidation of 5mC to 5hmC can technically be deemed as demethylation, thereby making 5hmC an intermediate molecule in the demethylation pathway, its presence in mammalian DNA certainly has biological relevance in the realm of gene activation and repression.
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